A study supported by the Foundation was recently highlighted on Ankylosing Spondylitis News. “Early initiation of anti-tumor necrosis factor (TNF) medications may be associated with an increased risk of cardiovascular events in people with ankylosing spondylitis (AS), a study suggests.”